Invitation to a Presentation of the 2 Quarter 2021 Results

Oncoinvent would like to extend an invitation to a presentation of the Q2 2021 results. The presentation will be held virtually via Teams at 09:00 on Thursday 9. September 2021.

We request that participants register with for logon details.

Organiser: Oncoinvent AS


Date: 9 September 2021

Jan Alan Alfheim

Chief Executive Officer

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.